NATTOKINASE

Nattokinase is the supplement form of a fermented soy food (see Foods Library). Its activity includes improvements in markers of metabolism of lipids and fats, but more importantly here its actions to improve vascular health. There is evidence of effective reduction in platelet aggregation and adhesion. But in particular, clotting mechanisms related to fibrin that are also linked to increased metastatic activity.

Trials also find a dose-dependency and a common dose of 2,000 FU/day is ineffective in reducing risk of stroke (atherosclerosis). In contrast, other studies demonstrated clear positive outcomes at a significantly higher dose of 10,800 FU/day. The higher dose regime is reported as effective in reducing stroke risk and hyperlipidemia, resulting in a significant reduction in the thickness of so plaque in measurable arteries. Improvement rates ranged from 66.5% to 95.4% at this higher dose. Importantly, the researchers find enhanced effects which given with vitamin K2 and low dose aspirin.

Also fascinating are synergies with the the statin class red yeast rice where the combination is effective reducing cholesterol, vascular coagulation and platelet adhesion. (Highlights). These results are promising as indirect evidence for reducing metastatic activity in cancer, by improving these crucial measurements for vascular health and reducing cancer related cholesterol activity.. This trials used clinical doses under medical supervision of 3662 FU plus 9mg monocolins, half with lunch half with dinner.

Lumbrokinase has similar mechanisms and might be considered as an alternative for some. A key distinguishing feature is its purported fibrin-specific mechanism, which may result in a lower risk of bleeding and higher compatibility with other anti-coagulants. It disrupts the formation of microclots and is in trials for long covid and other viral syndomes for this reason.

Research states its actions are complementary to aspirin, though of course use of anti-coagulation levels can require careful monitoring. These supplements should be avoided ahead of surgery, with blood pressure medications or if taking warfarin or other blood thinning drugs. A commercial formula NSK-SD has done safety testing, and is also an interesting alternative here, but consult with your medical advisor on natto or lumbrokinase.

TYPICAL ABSORPTION LEVELS

High

EXAMPLES OF IMPROVED OUTCOMES

PRE-DIAGNOSIS OR PREVENTION

Highlighted Studies

NK + RYR and NK groups had significantly better-improved lactate dehydrogenase than the others. NK + RYR group also showed more potent reductions in thromboxane B2 and increases in antithrombin III compared to placebo. These improved markers suggest that combined NK and RYR may preferably alter antithrombin and COX-1 pathways, potentially reducing thrombosis risks in CAD patients. Overall, the combined NK and RYR supplementation is safe and more effective than separately in improving ...

Link

Factor VIII activity declined at 4 and 6 hours (p < 0.05, respectively), blood antithrombin concentration was higher at 2 and 4 hours (p < 0.05, respectively), and the activated partial thromboplastin time prolonged significantly at 2 and 4 hours following NK administration (p < 0.05 and p < 0.01, respectively). All the changes, however, were within the normal range. In conclusion, thus, a single-dose of NK administration appears enhancing fibrinolysis and an...

Link

All of the measurements of blood lipids were changed significantly in the subjects taking the combined formula for one month, including: TG [triglycerides] decreasing by 22.8±36.9 mg/dL (15%), TC [total cholesterol] by 55.1±25.7 mg/dL (25%), LDLC by 56.0±21.0 mg/dL (41%, p<0.01) and HDL-C increasing by 4.1±8.2 mg/dL (7.5%, p=0.021) at month 1; these changes were sustained until the end of study. In particular, TG and HDL-C changed continuously..The result suggested that the combined fo...

Link

We found that NK at a dose of 10,800 FU/day effectively managed the progression of atherosclerosis and hyperlipidemia with a significant improvement in the lipid profile. A significant reduction in the thickness of the carotid artery intima-media and the size of the carotid plaque was observed. The improvement rates ranged from 66.5 to 95.4%. NK was found to be ineffective in lowering lipids and suppressing atherosclerosis progression at a dose of 3,600 FU/day… Regular exercise further ...

Link
BACK TO INDEX

TABLE OF REFERENCES

Help grow the evidence. Login and use the form, or try Feedback and Ideas below.

URLRatingHighlightHighlight 2
https://pmc.ncbi.nlm.nih.gov/articles/PMC9441630/3In this clinical study involving 1,062 participants, our objective was to examine the efficacy of NK in atherosclerosis and hyperlipidemia and safety at the dose of 10,800 FU/day after 12 months of oral administration. Various factors, including lower doses that influence NK pharmacological actions, were also investigated. We found that NK at a dose of 10,800 FU/day effectively managed the progression of atherosclerosis and hyperlipidemia with a significant improvement in the lipid profile. A significant reduction in the thickness of the carotid artery intima-media and the size of the carotid plaque was observed. The improvement rates ranged from 66.5 to 95.4%. NK was found to be ineffective in lowering lipids and suppressing atherosclerosis progression at a dose of 3,600 FU/day. No noticeable adverse effects associated with the use of NK were recorded. In conclusion, our data demonstrate that atherosclerosis progression and hyperlipidemia can be effectively managed with NK at a dose of 10,800 FU/day. The lower dose of 3,600 FU per day is ineffective. The dose of 10,800 FU/day is safe and well tolerated. Some lifestyle factors and the coadministration of vitamin K2 and aspirin lead to improved outcomes in the use of NK. Our findings provide clinical evidence on the effective dose of NK in the management of cardiovascular disease and challenge the recommended dose of 2,000 FU per day.
https://pmc.ncbi.nlm.nih.gov/articles/PMC11133624/2.5NK + RYR group also showed more potent reductions in thromboxane B2 and increases in antithrombin III compared to placebo (both p < 0.01). These improved markers suggest that combined NK and RYR may preferably alter antithrombin and COX-1 pathways, potentially reducing thrombosis risks in CAD patients. Overall, the combined NK and RYR supplementation is safe and more effective than separately in improving cardiometabolic markers among CAD patients with multiple heart medications use.In our analysis of blood coagulation markers, we have found that both TXB2 and 6-keto-PGF1α levels have decreased, while AT-III levels have increased in all groups after the 90-day intervention compared to baseline levels (Figure 2A). In comparisons of the change magnitudes across groups, we found that compared to the placebo group, the NK + RR group showed a significantly larger decrease in both TXB2 and 6-keto-PGF1α levels (p < 0.001 for both), and a significantly larger increase in AT-III. Compared to the placebo group, the RR group had a smaller decrease in the 6-keto-PGF1α level
https://www.researchgate.net/publication/3379263052.5In vivo and vitro studies have found potent fibrinolytic activity of nattokinase. Rodent studies reported that it is four times more effective than plasmin in dissolving a thrombus. Human studies have reported that oral nattokinase supplementation lead to thrombolysis and increased anti-coagulation factors. In addition, supplementation of nattokinase significantly decreased levels of fibrinogen, factor VII and factor VIII in subjects with cardiovascular diseaseNattokinase also has been shown to ameliorate blood viscosity, which lowers risk for cardiovascular disease. It is the purpose of this paper to review the studies related to nattokinase sup-plementation for its impact on reducing platelet aggregation and enhancing fibrinolytic activity in maintaining homeostatic balance.
https://pmc.ncbi.nlm.nih.gov/articles/PMC4479826/2Factor VIII activity declined at 4 and 6 hours (p < 0.05, respectively), blood antithrombin concentration was higher at 2 and 4 hours (p < 0.05, respectively), and the activated partial thromboplastin time prolonged significantly at 2 and 4 hours following NK administration (p < 0.05 and p < 0.01, respectively). All the changes, however, were within the normal range. In conclusion, thus, a single-dose of NK administration appears enhancing fibrinolysis and anti-coagulation via several different pathways simultaneouslyRecently, Ero and colleagues presented the first bioavailability data of NK in human by enzyme-linked immunosorbent assay9. Following 2,000 FU NK administration (the same amount as in our current study), they demonstrated NK serum activity between 2 through to 24 hours in healthy subjects. Our data, which confirmed an increase in activity of fibrinolysis and anticoagulant parameters between 2 and 8 hours after NK intake, is consistent with their results.
https://apjcn.nhri.org.tw/server/APJCN/18/3/310.pdf1.5In summary, this study provides long-term efficacy of nattokinase supplementation and shows that the combined formula has relatively more potent effects than the mono formula on lowering of blood lipids, suggesting that combined nattokinase with RYR will be a better neutraceutical for patients with hyperlipidemia than nattokinase alone. In the combined group significant decreases were found with regard to: triglycerides (TG) by 15%, total cholesterol (TC) by 25%, low-density lipoprotein cholesterol (LDL-C) by 41%, TC/high-density lipoprotein cholesterol (HDL-C) ratio by 29.5%, and increases in HDL-C by 7.5%. These changes were sustained until the end of study
https://www.dovepress.com/article/download/294081.5 Consumption of nattokinase was associated with a reduction in both systolic and diastolic BP. The reduction in systolic BP was seen for both sexes but was more robust in males consuming nattokinase. The average reduction in diastolic BP in the nattokinase group from 87 mmHg to 84 mmHg was statistically significant when compared to that in the group consuming placebo, where the average diastolic BP remained constant at 87 mmHg (P<0.05), and reached a high level of significance for males consuming nattokinase, where the average diastolic BP dropped from 86 mmHg to 81 mmHg (P<0.006). A decrease in vWF was seen in the female population consuming nattokinaseThe lowering of diastolic BP in males generated the most statistically significant and clinically important results in this study. The overall data suggest that the oral consumption of nattokinase supports healthy BP in both sexes, in a non-Asian population. In addition, the reduction in elevated vWF in the female subgroup suggests a possible reduction of risk for stroke. This is important, since previous studies were conducted in Asia where different genetic, dietary, and lifestyle factors contribute to hypertension
https://www.sciencedirect.com/science/article/pii/S2213453024001903N/AThrombotic complication is a major cause of mortality in cancer patients such as colon cancer patients[76]. Cancer-associated thrombosis (CAT) prevents drug from reaching the diseased tissue and prevents immune cells from detecting and attacking tumors. Therefore, treatment of CAT is an important aspect of cancer therapy. In view of the strong fibrinolytic activity of NK, several studies combined NK with anti-tumor drugs[77], [78]. They demonstrated that co-treatment with NK and a common anti-cancer drug doxorubicin (DOX) induced a greater anti-tumor effectsNK may also play a beneficial role as anti-cancer compound. In hepatocellular carcinoma (HCC) mice model, NK was shown to inhibit tumor growth and cell proliferation, which improved the survival rate of HCC mice[74]. Additionally, NK showed significant inhibitory effect on a murine breast carcinoma characterized by inhibiting breast cancer growth and reducing the expressions of oncogenic transcription factor FOXM1

Help grow the community

Join the Pubmedders subscriber base

Get our monthly email newletter – designed so you can give us your opinions, thoughts and feedback…

ALL contributions are invested into growing the site to help others.